Newer N-phthaloyl GABA derivatives with antiallodynic and antihyperalgesic activities in both sciatic nerve and spinal nerve ligation models of neuropathic pain

Perumal Yogeeswari, Jegadeesan Vaigunda Ragavendran, Dharmarajan Sriram, Ramkumar Kavya, Kaliappan Vanitha, Harshini Neelakantan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: There is considerable research evidence supporting a palliative role for γ-aminobutyric acid (GABA)-ergic neurotransmission and voltage-gated sodium channel blockade in neuropathic pain conditions. Hence, the present study was undertaken to assess the peripheral analgesic, antiallodynic and antihyperalgesic activities of the synthesized structural analogues of GABA. Methods: The screening study included acute tissue injury, chronic constriction injury (CCI), and spinal nerve ligation (SNL) models of neuropathic pain. Results: All of the tested compounds sup-pressed the acetic acid-induced writhing response significantly in comparison to the control. In particular, compound JVP-8 was observed to be the most active compound with percent inhibition greater than that of the standard drug aspirin (97.8% inhibition of writhing response as against 97.0% shown by aspirin). In neuropathic pain studies, compound JVP-5 (100 mg/kg i.p.) emerged as the most active compound affording maximum protection against dynamic allodynia and mechanical hyperalgesia in the CCI model, and against spontaneous pain and mechanical hyperalgesia in SNL rats. Conclusion: In this study, we have demonstrated that combining phthalimide pharmacophore with GABA has evolved compounds effective for the treatment of neuropathic pain.

Original languageEnglish (US)
Pages (from-to)21-31
Number of pages11
JournalPharmacology
Volume81
Issue number1
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Spinal Nerves
Neuralgia
Sciatic Nerve
Ligation
Hyperalgesia
gamma-Aminobutyric Acid
Constriction
Aspirin
Wounds and Injuries
Voltage-Gated Sodium Channels
Aminobutyrates
Synaptic Transmission
Acetic Acid
Analgesics
Pain
N-phthaloyl-4-aminobutyric acid
Research
Pharmaceutical Preparations
Inhibition (Psychology)
Therapeutics

Keywords

  • Allodynia
  • GABA
  • Hyperalgesia
  • Neuropathic pain
  • Peripheral nerve injury
  • Writhing response

ASJC Scopus subject areas

  • Pharmacology

Cite this

Newer N-phthaloyl GABA derivatives with antiallodynic and antihyperalgesic activities in both sciatic nerve and spinal nerve ligation models of neuropathic pain. / Yogeeswari, Perumal; Ragavendran, Jegadeesan Vaigunda; Sriram, Dharmarajan; Kavya, Ramkumar; Vanitha, Kaliappan; Neelakantan, Harshini.

In: Pharmacology, Vol. 81, No. 1, 11.2007, p. 21-31.

Research output: Contribution to journalArticle

Yogeeswari, Perumal ; Ragavendran, Jegadeesan Vaigunda ; Sriram, Dharmarajan ; Kavya, Ramkumar ; Vanitha, Kaliappan ; Neelakantan, Harshini. / Newer N-phthaloyl GABA derivatives with antiallodynic and antihyperalgesic activities in both sciatic nerve and spinal nerve ligation models of neuropathic pain. In: Pharmacology. 2007 ; Vol. 81, No. 1. pp. 21-31.
@article{764a1148ef34466eb2ffe174069e38e0,
title = "Newer N-phthaloyl GABA derivatives with antiallodynic and antihyperalgesic activities in both sciatic nerve and spinal nerve ligation models of neuropathic pain",
abstract = "Background: There is considerable research evidence supporting a palliative role for γ-aminobutyric acid (GABA)-ergic neurotransmission and voltage-gated sodium channel blockade in neuropathic pain conditions. Hence, the present study was undertaken to assess the peripheral analgesic, antiallodynic and antihyperalgesic activities of the synthesized structural analogues of GABA. Methods: The screening study included acute tissue injury, chronic constriction injury (CCI), and spinal nerve ligation (SNL) models of neuropathic pain. Results: All of the tested compounds sup-pressed the acetic acid-induced writhing response significantly in comparison to the control. In particular, compound JVP-8 was observed to be the most active compound with percent inhibition greater than that of the standard drug aspirin (97.8{\%} inhibition of writhing response as against 97.0{\%} shown by aspirin). In neuropathic pain studies, compound JVP-5 (100 mg/kg i.p.) emerged as the most active compound affording maximum protection against dynamic allodynia and mechanical hyperalgesia in the CCI model, and against spontaneous pain and mechanical hyperalgesia in SNL rats. Conclusion: In this study, we have demonstrated that combining phthalimide pharmacophore with GABA has evolved compounds effective for the treatment of neuropathic pain.",
keywords = "Allodynia, GABA, Hyperalgesia, Neuropathic pain, Peripheral nerve injury, Writhing response",
author = "Perumal Yogeeswari and Ragavendran, {Jegadeesan Vaigunda} and Dharmarajan Sriram and Ramkumar Kavya and Kaliappan Vanitha and Harshini Neelakantan",
year = "2007",
month = "11",
doi = "10.1159/000107711",
language = "English (US)",
volume = "81",
pages = "21--31",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Newer N-phthaloyl GABA derivatives with antiallodynic and antihyperalgesic activities in both sciatic nerve and spinal nerve ligation models of neuropathic pain

AU - Yogeeswari, Perumal

AU - Ragavendran, Jegadeesan Vaigunda

AU - Sriram, Dharmarajan

AU - Kavya, Ramkumar

AU - Vanitha, Kaliappan

AU - Neelakantan, Harshini

PY - 2007/11

Y1 - 2007/11

N2 - Background: There is considerable research evidence supporting a palliative role for γ-aminobutyric acid (GABA)-ergic neurotransmission and voltage-gated sodium channel blockade in neuropathic pain conditions. Hence, the present study was undertaken to assess the peripheral analgesic, antiallodynic and antihyperalgesic activities of the synthesized structural analogues of GABA. Methods: The screening study included acute tissue injury, chronic constriction injury (CCI), and spinal nerve ligation (SNL) models of neuropathic pain. Results: All of the tested compounds sup-pressed the acetic acid-induced writhing response significantly in comparison to the control. In particular, compound JVP-8 was observed to be the most active compound with percent inhibition greater than that of the standard drug aspirin (97.8% inhibition of writhing response as against 97.0% shown by aspirin). In neuropathic pain studies, compound JVP-5 (100 mg/kg i.p.) emerged as the most active compound affording maximum protection against dynamic allodynia and mechanical hyperalgesia in the CCI model, and against spontaneous pain and mechanical hyperalgesia in SNL rats. Conclusion: In this study, we have demonstrated that combining phthalimide pharmacophore with GABA has evolved compounds effective for the treatment of neuropathic pain.

AB - Background: There is considerable research evidence supporting a palliative role for γ-aminobutyric acid (GABA)-ergic neurotransmission and voltage-gated sodium channel blockade in neuropathic pain conditions. Hence, the present study was undertaken to assess the peripheral analgesic, antiallodynic and antihyperalgesic activities of the synthesized structural analogues of GABA. Methods: The screening study included acute tissue injury, chronic constriction injury (CCI), and spinal nerve ligation (SNL) models of neuropathic pain. Results: All of the tested compounds sup-pressed the acetic acid-induced writhing response significantly in comparison to the control. In particular, compound JVP-8 was observed to be the most active compound with percent inhibition greater than that of the standard drug aspirin (97.8% inhibition of writhing response as against 97.0% shown by aspirin). In neuropathic pain studies, compound JVP-5 (100 mg/kg i.p.) emerged as the most active compound affording maximum protection against dynamic allodynia and mechanical hyperalgesia in the CCI model, and against spontaneous pain and mechanical hyperalgesia in SNL rats. Conclusion: In this study, we have demonstrated that combining phthalimide pharmacophore with GABA has evolved compounds effective for the treatment of neuropathic pain.

KW - Allodynia

KW - GABA

KW - Hyperalgesia

KW - Neuropathic pain

KW - Peripheral nerve injury

KW - Writhing response

UR - http://www.scopus.com/inward/record.url?scp=36248992805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248992805&partnerID=8YFLogxK

U2 - 10.1159/000107711

DO - 10.1159/000107711

M3 - Article

VL - 81

SP - 21

EP - 31

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 1

ER -